bavisant: Clinical Trials

5 trials of bavisant, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 withdrawn. 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 15Completed 4, Withdrawn 1

Follow bavisant: new trials by email Literature Review of bavisant trials Research Report on bavisant

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Drug Interaction Study of JNJ-31001074 and Ketoconazole in Healthy Volunteers
JNJ-31001074; ketoconazole - Healthy, Pharmacokinetics
Phase 1CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.142009-11-012010-04-30
A Study to Characterize the Pharmacokinetics and Effect of Food on JNJ-31001074 in Healthy Volunteers
JNJ-31001074 - Healthy, Pharmacokinetics
Phase 1CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.202009-06-012010-04-26
A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of JNJ-31001074 in Pediatric Patients (12-17 Years) With Attention Deficit Hyperactivity Disorder (ADHD)
JNJ-31001074 - Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity
Phase 1CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.182009-05-012010-04-16
A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of of JNJ-31001074 in Children (6-11 Years) With Attention Deficit Hyperactivity Disorder (ADHD)
JNJ-31001074 - Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity
Phase 1CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.182009-05-012010-04-16
A Study to Evaluate the Pharmacokinetic Drug Interaction Between Multiple Doses of JNJ-31001074 and a Single Dose of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Women
JNJ-31001074 - Pharmacokinetics, Drug Interactions
Phase 1WithdrawnJohnson & Johnson Pharmaceutical Research & Development, L.L.C.2016-09-20

Conditions studied

Attention Deficit Disorder with Hyperactivity (2)

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (5)